Hematopoiesis: Definition, Stages, Sites, and Flowchart

Every second, your bone marrow makes roughly two to three million new red blood cells, along with large numbers of white cells and platelets, to replace the ones that wear out. That constant, high-volume manufacturing is hematopoiesis. When it slows, the body runs short of oxygen-carrying cells, infection-fighting cells, or clotting cells; when it runs out of control, the result is leukemia. Almost all of hematology begins here.

Hematopoiesis

Hematopoiesis, from the Greek haima (blood) and poiesis (to produce), is the process by which the body forms all of its mature blood cells, red blood cells, white blood cells, and platelets, from a single kind of precursor called the hematopoietic stem cell (HSC). It begins in the embryo and continues for life, in the red bone marrow in adults, producing billions of new cells every day to support oxygen transport, immune defense, and clotting.

For microbiology and medical students, hematopoiesis is the foundation for understanding how the body maintains its blood cells and responds to infection and injury.

Where does hematopoiesis occur

In adults, the primary site of hematopoiesis is the red bone marrow, mainly in the flat bones (sternum, ribs, pelvis, skull, and vertebrae) and the ends of the long bones. The site changes with age before birth: it begins in the yolk sac in the first few weeks, moves to the liver and spleen in mid-fetal life, and settles in the bone marrow from about the fifth month of gestation onward, where it remains for life.

Stages of hematopoiesis

Hematopoiesis is driven by hematopoietic stem cells (HSCs), multipotent cells that can either self-renew or differentiate into progenitor cells that mature into specialized blood cells. Where this happens shifts through three overlapping phases before birth, and then stays in the bone marrow for life.

Mesoblastic (yolk sac) phase

Hematopoiesis begins around day 19 of development, in the blood islands of the yolk sac. This primitive phase produces mainly large, nucleated red cells for early oxygen transport, along with early myeloid cells that seed long-lived tissue populations such as microglia and Langerhans cells. It lasts until about the eighth week. In parallel, the first definitive HSCs (the ones that will sustain blood formation for life) arise inside the embryo in the aorta-gonad-mesonephros (AGM) region, from the wall of the dorsal aorta, and then migrate to colonize the liver and, later, the bone marrow.

Hepatic phase

From about the fifth to sixth week, hematopoiesis shifts to the liver and later the spleen. The first definitive, adult-type blood cells appear here, and HSCs differentiate into both myeloid and lymphoid lineages. The liver remains a major site through mid-fetal life.

Medullary (bone marrow) phase

From about the sixteenth to twentieth week (the fifth month), the bone marrow becomes the main site and remains so after birth. In children, active red marrow fills most bones because the demand for red cells is high. In adults, it is confined mainly to the flat bones (sternum, ribs, pelvis, skull, and vertebrae) and the ends (metaphyses) of the long bones. Under stress or in bone marrow failure, hematopoiesis can revert to the liver and spleen, which is called extramedullary hematopoiesis.

Memory hook for the sequence: blood formation moves from the Yolk sac, to the Liver and spleen, to the Bones (Young Livers Build blood).

Stages of Hematopoiesis

Hematopoiesis is a dynamic process that occurs in different locations and stages throughout life, driven by hematopoietic stem cells (HSCs). These multipotent cells can self-renew or differentiate into progenitor cells, which mature into specialized blood cells.

Hematopoietic Stem Cells (HSCs)

Figure: Flow chart of hematopoietic cell divisions in the bone marrow.

HSCs are specialized, multipotent cells in the bone marrow and peripheral blood capable of:

• Self-Renewal: Producing identical HSCs to maintain their population.
• Differentiation: Developing into progenitor cells that form mature RBCs, WBCs, or platelets.

HSCs can remain quiescent (dormant) to avoid exhaustion, activating in response to injury or infection to increase blood cell production. Two models explain their fate:

• Stochastic Model: HSC differentiation is random.
• Instructive Model: Microenvironmental signals (e.g., cytokines) guide differentiation.

HSCs include:

• Long-Term HSCs: Primarily self-renew, ensuring a lifelong stem cell pool.
• Short-Term HSCs: Differentiate into multilineage progenitors, such as common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs).

Hematopoietic Microenvironment (Niche)

The bone marrow microenvironment, or niche, regulates hematopoiesis through cellular and molecular interactions. Key components include:

Bone Marrow Stromal Cells

• Fibroblasts, Adipocytes, Endothelial Cells, Osteoblasts: Provide structural support and secrete signaling molecules.
• Function: Support HSC survival, proliferation, and differentiation.

Cytokines and Growth Factors

Memory hook for the two best-known hormones: EPO comes from the kidnEy and drives red cells; TPO comes from the Liver and drives plateLets.

Extracellular Matrix (ECM)

• Composed of proteins like collagen, fibronectin, and laminin.
• Binds to HSC integrins, regulating cell adhesion, migration, and behavior.

Niches

• Endosteal Niche: Rich in osteoblasts, maintains HSC quiescence.
• Vascular Niche: Contains endothelial and perivascular cells, promotes HSC activation and mobilization.

Hematopoiesis Processes

HSCs differentiate into two main lineages:

• Common Myeloid Progenitors (CMPs): Produce RBCs (erythropoiesis), platelets (thrombopoiesis), and myeloid cells like granulocytes (neutrophils, basophils, eosinophils) or agranulocytes (macrophages, monocytes) via myelopoiesis.
• Common Lymphoid Progenitors (CLPs): Form lymphocytes (T, B, NK cells) through lymphopoiesis.

Each process is identified by specific cell surface markers (e.g., CD markers) for stem cells, progenitors, and mature cells.

Regulation of Hematopoiesis

Hematopoiesis is tightly regulated by intrinsic and extrinsic factors to maintain balanced blood cell production.

Intrinsic Regulators

• Transcription Factors:

GATA-1: Drives erythroid and megakaryocyte differentiation.
PU.1: Supports myeloid and lymphoid development.
RUNX1: Regulates HSC development and all lineages.

• Epigenetic Modifications:

DNA Methylation: Controls gene expression for lineage commitment.
Histone Modifications: Affect chromatin structure and gene activity.
MicroRNAs: Regulate HSC maintenance and differentiation.

• Signaling Pathways:

Notch Signaling: Influences HSC fate via cell-cell interactions.
Wnt Signaling: Regulates self-renewal and differentiation.

Extrinsic Regulators

• Cytokines/Growth Factors: SCF, EPO, G-CSF, and TPO drive specific cell production.
• Cell-Cell Interactions: Stromal cells, osteoblasts, and endothelial cells interact with HSCs via adhesion molecules (e.g., integrins, cadherins).
• Systemic Factors:

Hormones: Glucocorticoids and thyroid hormones influence hematopoiesis.
Nutritional Status: Vitamins (B12, folate) and iron are essential.
Immune Signals: Cytokines (e.g., interleukins) boost immune cell production during infection.

Feedback Mechanisms

• Negative Feedback: High RBC levels reduce EPO production; mature immune cells inhibit further production via cytokines.
• Homeostatic Balance: Ensures physiological blood cell levels.

Clinical Relevance of Hematopoiesis

Disruptions in hematopoiesis can lead to serious disorders, impacting blood cell production and function.

Anemias

• Aplastic Anemia: Bone marrow failure causing pancytopenia (low RBCs, WBCs, platelets). Symptoms: fatigue, infections, bleeding. Treatments: immunosuppressive therapy, bone marrow transplants.
• Iron-Deficiency Anemia: Reduced hemoglobin due to low iron. Symptoms: fatigue, pallor. Treatments: iron supplements, dietary changes.
• Megaloblastic Anemia: Vitamin B12/folate deficiency causing abnormal RBCs. Symptoms: fatigue, neurological issues. Treatments: B12/folate supplements.

Leukemias

• Acute Myeloid Leukemia (AML): Excessive myeloid blasts. Symptoms: fatigue, infections. Treatments: chemotherapy, bone marrow transplants.
• Acute Lymphoblastic Leukemia (ALL): Lymphoid precursor proliferation. Symptoms: fever, bone pain. Treatments: chemotherapy, targeted therapies.
• Chronic Myeloid Leukemia (CML): Caused by BCR-ABL gene. Symptoms: fatigue, splenomegaly. Treatments: tyrosine kinase inhibitors (e.g., imatinib).
• Chronic Lymphocytic Leukemia (CLL): B lymphocyte proliferation. Symptoms: lymphadenopathy, fatigue. Treatments: chemotherapy, targeted therapies.

Myelodysplastic Syndromes (MDS)

Ineffective hematopoiesis with AML risk. Symptoms: anemia, infections. Treatments: transfusions, growth factors, stem cell transplants.

Myeloproliferative Neoplasms (MPNs)

• Polycythemia Vera (PV): Excessive RBCs due to JAK2 mutation. Symptoms: headaches, thrombosis risk. Treatments: phlebotomy, JAK2 inhibitors.
• Essential Thrombocythemia (ET): Platelet overproduction. Symptoms: thrombosis, bleeding. Treatments: aspirin, cytoreductive therapy.
• Primary Myelofibrosis (PMF): Bone marrow fibrosis. Symptoms: anemia, splenomegaly. Treatments: JAK2 inhibitors, stem cell transplants.

Lymphomas

• Hodgkin Lymphoma: B cell malignancy with Reed-Sternberg cells. Symptoms: lymphadenopathy, fever. Treatments: chemotherapy, radiation.
• Non-Hodgkin Lymphoma: Diverse lymphoid malignancies. Symptoms: lymphadenopathy, weight loss. Treatments: chemotherapy, targeted therapies.

Bone Marrow Failure Syndromes

• Fanconi Anemia: Genetic disorder causing pancytopenia. Symptoms: congenital anomalies, cancer risk. Treatments: stem cell transplants.
• Diamond-Blackfan Anemia: Congenital RBC deficiency. Symptoms: severe anemia. Treatments: corticosteroids, transfusions.

Hematopoiesis in Clinical Practice

• Leukemia: Malignant cells disrupt the bone marrow niche, impairing normal hematopoiesis.
• Bone Marrow Transplantation: Requires a supportive niche for donor HSCs, using conditioning regimens and growth factors for engraftment.

Where students get confused

Hematopoiesis is not the same as erythropoiesis. Hematopoiesis is the formation of all blood cells. Erythropoiesis is only the red cell branch of it. Likewise leukopoiesis (white cells) and thrombopoiesis (platelets) are branches, not synonyms.

"Myeloid" has two meanings. It usually means the non-lymphoid lineage (red cells, platelets, granulocytes, and monocytes), which is how it is used in the common myeloid progenitor. It is also used loosely to mean "of the bone marrow." Acute myeloid leukemia refers to the lineage, not just the location.

Common myeloid progenitor (CMP) versus common lymphoid progenitor (CLP). These are the first branch point. CMP gives red cells, platelets, granulocytes, and monocytes; CLP gives B cells, T cells, and NK cells. Keep the two branches straight.

Primary versus secondary lymphoid organs. Hematopoiesis happens in a primary lymphoid organ (bone marrow), where cells are made and mature. Secondary lymphoid organs (lymph nodes, spleen) are where mature cells meet antigen, not where they form.

Red versus yellow marrow. Red marrow is hematopoietically active. Yellow (fatty) marrow is inactive but can reconvert to red marrow under demand, such as chronic anemia.

Endosteal versus vascular niche. The endosteal (osteoblastic) niche keeps stem cells quiet and reserved; the vascular (sinusoidal) niche supports active proliferation and release into blood. Same marrow, two microenvironments with opposite jobs.

References

1. Jagannathan-Bogdan M, Zon LI. Hematopoiesis. Development. 2013;140(12):2463-2467. https://doi.org/10.1242/dev.083147
2. Chapman J, Zhang Y. Histology, Hematopoiesis. In: StatPearls. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK534246/
3. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35-71. https://doi.org/10.1146/annurev.cb.11.110195.000343
4. Greenberger JS. The hematopoietic microenvironment. Crit Rev Oncol Hematol. 1991;11(1):65-84. https://doi.org/10.1016/1040-8428(91)90018-8
5. Gaballa M, Ramos CA. Overview of normal hematopoiesis. In: Handbook of Benign Hematology. Springer Publishing; 2019. https://doi.org/10.1891/9780826149879.0001
6. Hoffbrand AV, Moss PAH. Hoffbrand's Essential Haematology. 8th ed. Wiley-Blackwell; 2019.
7. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2021.